Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies
Open Access
Abstract
No abstract availableKeywords
Funding Information
- CSL Behring
- Seqirus
This publication has 30 references indexed in Scilit:
- Superior Effectiveness and Estimated Public Health Impact of Cell- Versus Egg-Based Influenza Vaccines in Children and Adults During the US 2023–2024 SeasonInfectious Diseases and Therapy, 2025
- A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and olderVaccine, 2025
- High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature ReviewAdvances in Therapy, 2023
- Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysiseClinicalMedicine, 2022
- Understanding immunosenescence and its impact on vaccination of older adultsVaccine, 2020
- A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza seasonVaccine, 2020
- A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of ageVaccine, 2020
- A Tale of Two Mutations: Beginning to Understand the Problems with Egg-Based Influenza Vaccines?Cell Host & Microbe, 2019
- Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older AdultsNew England Journal of Medicine, 2014
- The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccinesVaccine, 2012